{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T21:16:07Z","timestamp":1770844567672,"version":"3.50.1"},"reference-count":45,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":["www.ahajournals.org"],"crossmark-restriction":true},"short-container-title":["Hypertension"],"published-print":{"date-parts":[[2020,4]]},"abstract":"<jats:p>\n            Previously, we showed that peripheral administration of 2-ME (2-methoxyestradiol), a CYP1B1 (cytochrome P450 1B1)-catechol-\n            <jats:italic>O<\/jats:italic>\n            -methyltransferase (COMT) generated metabolite of E2 (17\u03b2-Estradiol), protects against angiotensin II-induced hypertension in female mice. The demonstration that central E2 inhibits angiotensin II-induced hypertension, together with the expression of CYP1B1 in the brain, led us to hypothesize that E2-CYP1B1 generated metabolite 2-ME in the brain mediates its protective action against angiotensin II-induced hypertension in female mice. To test this hypothesis, we examined the effect of intracerebroventricularly (ICV) administered E2 in ovariectomized (OVX)-wild-type (\n            <jats:italic>Cyp1b1<\/jats:italic>\n            <jats:sup>+\/+<\/jats:sup>\n            ) and OVX-\n            <jats:italic>Cyp1b1<\/jats:italic>\n            <jats:sup>\u2212\/\u2212<\/jats:sup>\n            mice on the action of systemic angiotensin II. ICV-E2 attenuated the angiotensin II-induced increase in mean arterial blood pressure, impairment of baroreflex sensitivity, and sympathetic activity in OVX-\n            <jats:italic>Cyp1b1<\/jats:italic>\n            <jats:sup>+\/+<\/jats:sup>\n            but not in ICV-injected short interfering (si)RNA-COMT or OVX-\n            <jats:italic>Cyp1b1<\/jats:italic>\n            <jats:sup>\u2212\/\u2212<\/jats:sup>\n            mice. ICV-2-ME attenuated the angiotensin II-induced increase in blood pressure in OVX-\n            <jats:italic>Cyp1b1<\/jats:italic>\n            <jats:sup>\u2212\/\u2212<\/jats:sup>\n            mice; this effect was inhibited by ICV-siRNA estrogen receptor-\u03b1 (ER\u03b1) and G protein-coupled estrogen receptor 1 (GPER1). ICV-E2 in OVX-\n            <jats:italic>Cyp1b1<\/jats:italic>\n            <jats:sup>+\/+<\/jats:sup>\n            but not in OVX-\n            <jats:italic>Cyp1b1<\/jats:italic>\n            <jats:sup>\u2212\/\u2212<\/jats:sup>\n            mice and 2-ME in the OVX-\n            <jats:italic>Cyp1b1<\/jats:italic>\n            <jats:sup>\u2212\/\u2212<\/jats:sup>\n            inhibited angiotensin II-induced increase in reactive oxygen species production in the subfornical organ and paraventricular nucleus, activation of microglia and astrocyte, and neuroinflammation in paraventricular nucleus. Furthermore, central CYP1B1 gene disruption in\n            <jats:italic>Cyp1b1<\/jats:italic>\n            <jats:sup>+\/+<\/jats:sup>\n            mice by ICV-adenovirus-GFP (green fluorescence protein)-CYP1B1-short hairpin (sh)RNA elevated, while reconstitution by adenovirus-GFP-CYP1B1-DNA in the paraventricular nucleus but not in subfornical organ in\n            <jats:italic>Cyp1b1<\/jats:italic>\n            <jats:sup>\u2212\/\u2212<\/jats:sup>\n            mice attenuated the angiotensin II-induced increase in systolic blood pressure. These data suggest that E2-CYP1B1-COMT generated metabolite 2-ME, most likely in the paraventricular nucleus via estrogen receptor-\u03b1 and GPER1, protects against angiotensin II-induced hypertension and neuroinflammation in female mice.\n          <\/jats:p>","DOI":"10.1161\/hypertensionaha.119.14548","type":"journal-article","created":{"date-parts":[[2020,3,11]],"date-time":"2020-03-11T18:00:36Z","timestamp":1583949636000},"page":"1054-1062","update-policy":"https:\/\/doi.org\/10.1161\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":27,"title":["Central CYP1B1 (Cytochrome P450 1B1)-Estradiol Metabolite 2-Methoxyestradiol Protects From Hypertension and Neuroinflammation in Female Mice"],"prefix":"10.1161","volume":"75","author":[{"given":"Purnima","family":"Singh","sequence":"first","affiliation":[{"name":"From the Department of Pharmacology, Addiction Science, and Toxicology, College of Medicine, University of Tennessee Health Science Center, Memphis (P.S., C.Y.S., S.R.D., K.U.M.)"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chi Young","family":"Song","sequence":"additional","affiliation":[{"name":"From the Department of Pharmacology, Addiction Science, and Toxicology, College of Medicine, University of Tennessee Health Science Center, Memphis (P.S., C.Y.S., S.R.D., K.U.M.)"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shubha Ranjan","family":"Dutta","sequence":"additional","affiliation":[{"name":"From the Department of Pharmacology, Addiction Science, and Toxicology, College of Medicine, University of Tennessee Health Science Center, Memphis (P.S., C.Y.S., S.R.D., K.U.M.)"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frank J.","family":"Gonzalez","sequence":"additional","affiliation":[{"name":"Laboratory of Metabolism, National Cancer Institute, Bethesda, MD (F.J.G.)."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kafait U.","family":"Malik","sequence":"additional","affiliation":[{"name":"From the Department of Pharmacology, Addiction Science, and Toxicology, College of Medicine, University of Tennessee Health Science Center, Memphis (P.S., C.Y.S., S.R.D., K.U.M.)"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"e_1_3_4_2_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.hyp.37.5.1199"},{"key":"e_1_3_4_3_2","doi-asserted-by":"publisher","DOI":"10.1186\/2042-6410-3-7"},{"key":"e_1_3_4_4_2","doi-asserted-by":"publisher","DOI":"10.1152\/ajpheart.00969.2004"},{"key":"e_1_3_4_5_2","doi-asserted-by":"publisher","DOI":"10.1096\/fasebj.7.8.8500693"},{"key":"e_1_3_4_6_2","doi-asserted-by":"publisher","DOI":"10.1113\/JP276223"},{"key":"e_1_3_4_7_2","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.113.01743"},{"key":"e_1_3_4_8_2","doi-asserted-by":"publisher","DOI":"10.1152\/ajpheart.01011.2005"},{"key":"e_1_3_4_9_2","doi-asserted-by":"publisher","DOI":"10.1152\/ajpregu.00406.2014"},{"key":"e_1_3_4_10_2","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.111.00903"},{"key":"e_1_3_4_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.yhbeh.2018.06.012"},{"key":"e_1_3_4_12_2","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.114.03275"},{"key":"e_1_3_4_13_2","first-page":"2269","article-title":"Is 2-methoxyestradiol an endogenous estrogen metabolite that inhibits mammary carcinogenesis?","volume":"58","author":"Zhu BT","year":"1998","unstructured":"Zhu, BT, Conney, AH. Is 2-methoxyestradiol an endogenous estrogen metabolite that inhibits mammary carcinogenesis? Cancer Res. 1998;58:2269\u20132277.","journal-title":"Cancer Res"},{"key":"e_1_3_4_14_2","doi-asserted-by":"publisher","DOI":"10.1152\/ajpendo.00418.2015"},{"key":"e_1_3_4_15_2","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.114.04803"},{"key":"e_1_3_4_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/s0006-8993(99)01672-8"},{"key":"e_1_3_4_17_2","doi-asserted-by":"publisher","DOI":"10.1002\/syn.21800"},{"key":"e_1_3_4_18_2","doi-asserted-by":"publisher","DOI":"10.1002\/cne.23569"},{"key":"e_1_3_4_19_2","doi-asserted-by":"publisher","DOI":"10.1152\/ajpheart.00502.2009"},{"key":"e_1_3_4_20_2","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.110.160564"},{"key":"e_1_3_4_21_2","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.109.144477"},{"key":"e_1_3_4_22_2","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.110.150409"},{"key":"e_1_3_4_23_2","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.116.07747"},{"key":"e_1_3_4_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2015.05.046"},{"key":"e_1_3_4_25_2","doi-asserted-by":"publisher","DOI":"10.1177\/002215540104900210"},{"key":"e_1_3_4_26_2","doi-asserted-by":"publisher","DOI":"10.1136\/mp.51.3.138"},{"key":"e_1_3_4_27_2","first-page":"593","article-title":"Catechol-O-methyltransferase (COMT): biochemistry, molecular biology, pharmacology, and clinical efficacy of the new selective COMT inhibitors.","volume":"51","author":"M\u00e4nnist\u00f6 PT","year":"1999","unstructured":"M\u00e4nnist\u00f6, PT, Kaakkola, S. Catechol-O-methyltransferase (COMT): biochemistry, molecular biology, pharmacology, and clinical efficacy of the new selective COMT inhibitors. Pharmacol Rev. 1999;51:593\u2013628.","journal-title":"Pharmacol Rev"},{"key":"e_1_3_4_28_2","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.117.09247"},{"key":"e_1_3_4_29_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.HYP.0000248754.67128.ff"},{"key":"e_1_3_4_30_2","doi-asserted-by":"publisher","DOI":"10.1152\/jappl.2001.91.4.1868"},{"key":"e_1_3_4_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2013.10.064"},{"key":"e_1_3_4_32_2","doi-asserted-by":"publisher","DOI":"10.1152\/ajpcell.00152.2017"},{"key":"e_1_3_4_33_2","doi-asserted-by":"publisher","DOI":"10.1210\/en.2016-1402"},{"key":"e_1_3_4_34_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsbmb.2017.04.012"},{"key":"e_1_3_4_35_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.genm.2012.01.008"},{"key":"e_1_3_4_36_2","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2019.00586"},{"key":"e_1_3_4_37_2","doi-asserted-by":"publisher","DOI":"10.1006\/frne.1994.1009"},{"key":"e_1_3_4_38_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchemneu.2009.05.008"},{"key":"e_1_3_4_39_2","doi-asserted-by":"publisher","DOI":"10.1152\/jn.00914.2002"},{"key":"e_1_3_4_40_2","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.119.13133"},{"key":"e_1_3_4_41_2","doi-asserted-by":"publisher","DOI":"10.1210\/en.2004-0619"},{"key":"e_1_3_4_42_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1471-4159.2010.06723.x"},{"key":"e_1_3_4_43_2","doi-asserted-by":"publisher","DOI":"10.1097\/SHK.0b013e318231866f"},{"key":"e_1_3_4_44_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.molbrainres.2004.10.043"},{"key":"e_1_3_4_45_2","doi-asserted-by":"publisher","DOI":"10.1093\/ajh\/hpy148"},{"key":"e_1_3_4_46_2","first-page":"130","article-title":"The immune system in hypertension.","volume":"125","author":"Harrison DG","year":"2014","unstructured":"Harrison, DG. The immune system in hypertension. Trans Am Clin Climatol Assoc. 2014;125:130\u2013138; discussion 138.","journal-title":"Trans Am Clin Climatol Assoc"}],"container-title":["Hypertension"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ahajournals.org\/doi\/full\/10.1161\/HYPERTENSIONAHA.119.14548","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,13]],"date-time":"2024-05-13T10:22:44Z","timestamp":1715595764000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ahajournals.org\/doi\/10.1161\/HYPERTENSIONAHA.119.14548"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4]]},"references-count":45,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,4]]}},"alternative-id":["10.1161\/HYPERTENSIONAHA.119.14548"],"URL":"https:\/\/doi.org\/10.1161\/hypertensionaha.119.14548","relation":{},"ISSN":["0194-911X","1524-4563"],"issn-type":[{"value":"0194-911X","type":"print"},{"value":"1524-4563","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,4]]},"assertion":[{"value":"2019-12-11","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-01-28","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-03-09","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}